Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience.
BACKGROUND
The purpose of this paper is to report real-world data on the relative effectiveness of a biosimilar erythropoiesis-stimulating agent (ESA; Binocrit(®)), and other available ESAs for the treatment of chemotherapy-induced anemia.


METHODS
Data were collected retrospectively from single centers in Spain (n=284) and Germany (n=145). Hemoglobin outcomes, transfusion requirements, and serious drug-related adverse events were assessed for each ESA.


RESULTS
Hemoglobin outcomes and transfusion requirements were generally similar in the different ESA treatment groups assessed. No serious drug-related adverse events were recorded in any of the treatment groups.


CONCLUSION
These data confirm the real-world effectiveness and safety of a biosimilar ESA (Binocrit(®)) for the treatment of cancer patients with chemotherapy-induced anemia.
['Rodriguez Garzotto|Analia|A|', 'Cortijo Casacajares|Susana|S|', 'Pernaut|Cristina|C|', 'Ruiz Ares|Gustavo Javier|GJ|', 'Otero Blas|Irene|I|', 'Heine|Oliver|O|', 'Turner|Matthew|M|', 'Rebollo Laserna|Francisco|F|', 'Cortes Funes|Hernan|H|', 'Lorenz|Andreas|A|']
erythropoiesis-stimulating agents chemotherapy-induced anemia biosimilar